Ad is loading...
ARCT
Price
$19.09
Change
+$1.24 (+6.95%)
Updated
Dec 6, 04:59 PM (EDT)
85 days until earnings call
GNMSF
Price
$212.50
Change
-$14.85 (-6.53%)
Updated
Dec 6 closing price
Ad is loading...

ARCT vs GNMSF

Header iconARCT vs GNMSF Comparison
Open Charts ARCT vs GNMSFBanner chart's image
Arcturus Therapeutics Holdings
Price$19.09
Change+$1.24 (+6.95%)
Volume$2.96K
CapitalizationN/A
Genmab A/S
Price$212.50
Change-$14.85 (-6.53%)
Volume$3.18K
CapitalizationN/A
ARCT vs GNMSF Comparison Chart
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ARCT vs. GNMSF commentary
Dec 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and GNMSF is a StrongSell.

COMPARISON
Comparison
Dec 08, 2024
Stock price -- (ARCT: $19.09 vs. GNMSF: $212.50)
Brand notoriety: ARCT and GNMSF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 131% vs. GNMSF: 48%
Market capitalization -- ARCT: $483.51M vs. GNMSF: $13.71B
ARCT [@Biotechnology] is valued at $483.51M. GNMSF’s [@Biotechnology] market capitalization is $13.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $489.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileGNMSF’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • GNMSF’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than GNMSF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish while GNMSF’s TA Score has 3 bullish TA indicator(s).

  • ARCT’s TA Score: 5 bullish, 3 bearish.
  • GNMSF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than GNMSF.

Price Growth

ARCT (@Biotechnology) experienced а +4.09% price change this week, while GNMSF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -2.68%, and the average quarterly price growth was +10.76%.

Reported Earning Dates

ARCT is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMSF($13.7B) has a higher market cap than ARCT($484M). GNMSF YTD gains are higher at: -32.689 vs. ARCT (-39.454). GNMSF has higher annual earnings (EBITDA): 6.97B vs. ARCT (-25.93M). GNMSF has more cash in the bank: 17.3B vs. ARCT (237M). ARCT has less debt than GNMSF: ARCT (29.4M) vs GNMSF (987M). GNMSF has higher revenues than ARCT: GNMSF (19.8B) vs ARCT (142M).
ARCTGNMSFARCT / GNMSF
Capitalization484M13.7B4%
EBITDA-25.93M6.97B-0%
Gain YTD-39.454-32.689121%
P/E RatioN/A20.53-
Revenue142M19.8B1%
Total Cash237M17.3B1%
Total Debt29.4M987M3%
FUNDAMENTALS RATINGS
ARCT vs GNMSF: Fundamental Ratings
ARCT
GNMSF
OUTLOOK RATING
1..100
2050
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
9456
PRICE GROWTH RATING
1..100
6282
P/E GROWTH RATING
1..100
10091
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (49) in the Pharmaceuticals Major industry is in the same range as GNMSF (66) in the null industry. This means that ARCT’s stock grew similarly to GNMSF’s over the last 12 months.

ARCT's Profit vs Risk Rating (88) in the Pharmaceuticals Major industry is in the same range as GNMSF (100) in the null industry. This means that ARCT’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's SMR Rating (56) in the null industry is somewhat better than the same rating for ARCT (94) in the Pharmaceuticals Major industry. This means that GNMSF’s stock grew somewhat faster than ARCT’s over the last 12 months.

ARCT's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as GNMSF (82) in the null industry. This means that ARCT’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's P/E Growth Rating (91) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that GNMSF’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTGNMSF
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
74%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 7 days ago
64%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
68%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
71%
View a ticker or compare two or three
Ad is loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LGLOX52.860.45
+0.86%
Lord Abbett Growth Leaders F3
GWILX18.360.15
+0.82%
Glenmede Women in Leadership US Eq
AWWIX13.39-0.03
-0.22%
CIBC Atlas International Growth Instl
STREX28.72-0.15
-0.52%
Sterling Capital Equity Income R6
GQHIX13.31-0.10
-0.75%
GQG Partners US Quality Dividend Inc Ins

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ABCL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+6.95%
ABCL - ARCT
49%
Loosely correlated
+5.26%
AXON - ARCT
49%
Loosely correlated
-0.30%
BMEA - ARCT
48%
Loosely correlated
-1.45%
BEAM - ARCT
45%
Loosely correlated
+5.49%
PGEN - ARCT
45%
Loosely correlated
+0.47%
More

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
-6.53%
GMAB - GNMSF
58%
Loosely correlated
-0.18%
RIGL - GNMSF
29%
Poorly correlated
-2.23%
ARCT - GNMSF
28%
Poorly correlated
+6.95%
ATNM - GNMSF
27%
Poorly correlated
+11.48%
AGIO - GNMSF
27%
Poorly correlated
+4.53%
More